Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.

ABSTRACT:

Background & aims

Two SARS-CoV-2 mRNA vaccines were approved to prevent COVID-19 infection, with reported vaccine efficacy of 95%. Liver transplant (LT) recipients are at risk of lower vaccine immunogenicity and were not included in the registration trials. We assessed vaccine immunogenicity and safety in this special population.

Methods

LT recipients followed at the Tel-Aviv Sourasky Medical Center and healthy volunteers were tested for SARS-CoV-2 IgG antibodies directed against the Spike-protein (S) and Nucleocapsid-protein (N) 10-20 days after receiving the second Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine dose. Information regarding vaccine side effects and clinical data was collected from patients and medical records.

Results

Eighty LT recipients were enrolled.

SUBMITTER: Rabinowich L 

PROVIDER: S-EPMC8058047 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature